| Literature DB >> 31150737 |
Fabio Penna1, Riccardo Ballarò2, Paula Martinez-Cristobal3, David Sala4, David Sebastian3, Silvia Busquets5, Maurizio Muscaritoli6, Josep M Argilés5, Paola Costelli2, Antonio Zorzano7.
Abstract
Cancer cachexia is a multifactorial syndrome characterized by anorexia, weight loss and muscle wasting that impairs patients' quality of life and survival. Aim of this work was to evaluate the impact of either autophagy inhibition (knocking down beclin-1) or promotion (overexpressing TP53INP2/DOR) on cancer-induced muscle wasting. In C26 tumor-bearing mice, stress-induced autophagy inhibition was unable to rescue the loss of muscle mass and worsened muscle morphology. Treating C26-bearing mice with formoterol, a selective β2-agonist, muscle sparing was paralleled by reduced static autophagy markers, although the flux was maintained. Conversely, the stimulation of muscle autophagy exacerbated muscle atrophy in tumor-bearing mice. TP53INP2 further promoted atrogene expression and suppressed mitochondrial dynamics-related genes. Excessive autophagy might impair mitochondrial function through mitophagy. Consistently, tumor-induced mitochondrial dysfunction was detected by reduced ex vivo muscle fiber respiration. Overall, the results evoke a central role for muscle autophagy in cancer-induced muscle wasting.Entities:
Keywords: autophagy; cancer cachexia; mitochondria; mitophagy; muscle wasting
Mesh:
Year: 2019 PMID: 31150737 DOI: 10.1016/j.jmb.2019.05.032
Source DB: PubMed Journal: J Mol Biol ISSN: 0022-2836 Impact factor: 5.469